Regeneron Pharmaceuticals, Inc. [REGN] stock prices are up 0.82% to $989.28 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The REGN shares have gain 4.35% over the last week, with a monthly amount glided 4.26%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 23, February 2024, Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation. In a post published today on Yahoo Finance, Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in more than a decade.
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc. [NASDAQ: REGN] stock has seen the most recent analyst activity on January 12, 2024, when RBC Capital Mkts upgraded its rating to a Outperform and also boosted its price target to $1076 from $884. Previously, Deutsche Bank started tracking the stock with Hold rating on November 09, 2023, and set its price target to $800. On November 03, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $950 on the stock. Canaccord Genuity upgraded its rating to a Buy and increased its price target to $992 on August 21, 2023. Oppenheimer reiterated its recommendation of a Perform and raised its price target to $1050 on August 21, 2023. Canaccord Genuity downgraded its rating to Hold for this stock on June 28, 2023, and downed its price target to $720. In a note dated March 27, 2023, SVB Securities upgraded an Outperform rating on this stock and boosted its target price from $834 to $976.
The stock price of Regeneron Pharmaceuticals, Inc. [REGN] has been fluctuating between $684.80 and $985.64 over the past year. Currently, Wall Street analysts expect the stock to reach $805.85 within the next 12 months. Regeneron Pharmaceuticals, Inc. [NASDAQ: REGN] shares were valued at $989.28 at the most recent close of the market. An investor can expect a potential drop of -18.54% based on the average REGN price forecast.
Analyzing the REGN fundamentals
The Regeneron Pharmaceuticals, Inc. [NASDAQ:REGN] reported sales of 13.12B for trailing twelve months, representing a surge of 0.58%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 977.53 points at the first support level, and at 965.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 998.50, and for the 2nd resistance point, it is at 1,007.72.
Regeneron Pharmaceuticals, Inc. [REGN] reported earnings per share of $11.86 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $10.73/share, meaning a difference of $1.13 and a surprise factor of 10.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $11.59 per share as compared to estimates of $10.72 per share, a difference of $0.87 representing a surprise of 8.10%.
Ratios To Look Out For
It’s worth pointing out that Regeneron Pharmaceuticals, Inc. [NASDAQ:REGN]’s Current Ratio is 5.69. In addition, the Quick Ratio stands at 4.94 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 8.28, the price to book ratio is 4.17 and price to earnings (TTM) ratio is 28.47.
Transactions by insiders
In the past 3 months, 0 insiders have purchased 0 shares, and 3 have sold 1,930 shares. Recent insider trading involved Bassler Bonnie L, Director, that happened on Feb 26 when 854.0 shares were sold. Director, SING GEORGE L completed a deal on Feb 23 to sell 500.0 shares. Meanwhile, Director SING GEORGE L sold 3000.0 shares on Feb 22.
